Clinical practice guidelines on iron therapy: A critical evaluation

Hemodialysis International

Volumn 21, Issue , 2017, Pages S125-S131

  Del Vecchio, Lucia ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

anaphylaxis; chronic kidney disease; erythropoiesis stimulating agents; guidelines; Iron

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; IRON;

ANAPHYLAXIS; BACTERIAL GROWTH; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; HUMAN; IRON DEFICIENCY; IRON THERAPY; REVIEW; ANEMIA; BLOOD; COMPLICATION; PRACTICE GUIDELINE;

ANEMIA; FERRITINS; HEMATINICS; HUMANS; IRON; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 85018708800     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12562     Document Type: Review

References (41)

1. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019–2032.
2. Iglehart JK. Bundled payment for ESRD — Including ESAs in Medicare's dialysis package. N Engl J Med. 2011; 364:593–595.
3. Zoccali C, Abramowicz D, Cannata-Andia JB, et al. European Best Practice Guidelines; European Renal Best Practice. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2008; 23:2162–1266.
4. Anaemia Work Group for National Kidney Foundation – Dialysis Outcomes Quality Initiative (NKF-DOQI): Clinical practice guidelines for the treatment of anaemia of chronic renal failure. Am J Kidney Dis. 1997; 30:192–240.
5. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999; 14:1–50.
6. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: Improving global outcomes. Kidney Int. 2004; 66:1310–1314.
7. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2:279–335.
8. Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference Participants. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016; 89:28–39.
9. Locatelli F, Bárány P, Covic A, et al. Kidney disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28:1346–1359.
10. Available from: http://www.cari.org.au/Dialysis/dialysis%20biochemical%20hematological/KHA_CARI_Guideline_Fe_in_CKD_16_July_2013.pdf (accessed date: March 7, 2017).
11. National Collaborating Centre for Chronic Conditions. Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. London: Royal College of Physicians, 2006.
12. Available from: https://www.nice.org.uk/guidance/ng8 (accessed date: February 21, 2017).
13. Toffelmire EB, Barrett BJ, Fenton SS, et al. Canadian Society of Nephrology Clinical Practice Guidelines. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol. 1999; 10:S287–S321.
14. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62:849–859.
15. Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis. 2013; 62:860–873.
16. Stancu S, Bârsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol. 2010; 5:409–416.
17. Ridefelt P, Larsson A, Rehman JU, Axelsson J. Influences of sleep and the circadian rhythm on iron-status indices. Clin Biochem. 2010; 43:1323–1328.
18. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21:991–998.
19. Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant. 2007; 22:794–800.
20. Locatelli F, Del Vecchio L, Casartelli D. Erythropoietin in kidney disease and type 2 diabetes. N Engl J Med. 2011; 364:384.
21. Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010; 55:639–647.
22. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014; 29:2075–2084.
23. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16:3070–3080.
24. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15:1623–1632.
25. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet. 1982; 1:652–655.
26. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012; 89:87–93.
27. Pisoni RL, Fuller DS, Bieber BA, Gillespie BW, Robinson BM. The DOPPS Practice Monitor for US dialysis care: Trends through August 2011. Am J Kidney Dis. 2012; 60:160–165.
28. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016; 9:260–267.
29. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18:975–984.
30. Kapoian T, O'mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19:372–379.
31. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19:1599–1605.
32. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1:CD007857.
33. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients. Semin Dial. 2014; 27:26–36.
34. Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014; 29:809–822.
35. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol. 2012; 36:50–57.
36. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. “Iron storage indices: Novel predictors of bacteriemia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis. 2004; 38:1090–1094.
37. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013; 24:1151–1158.
38. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ. 2013; 347:f4822.
39. Brewster UC, Coca SG, Reilly RF, Perazella MA. Effect of intravenous iron on hemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton). 2005; 10:124–128.
40. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteriemia in chronic hamodialysis patients. Clin Nephrol. 2002; 57:457–461.
41. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001833.jsp&mid=WC0b01ac058004d5c1 (accessed date: January 26, 2015).